Tesetaxel as First-line Therapy for Metastatic Breast Cancer

This study is currently recruiting participants.
Verified July 2012 by Genta Incorporated
Sponsor:
Information provided by (Responsible Party):
Genta Incorporated
ClinicalTrials.gov Identifier:
NCT01221870
First received: October 13, 2010
Last updated: July 20, 2012
Last verified: July 2012

October 13, 2010
July 20, 2012
November 2010
October 2012   (final data collection date for primary outcome measure)
Response rate (revised RECIST) [ Time Frame: 12 months from date of first dose of study medication for last patient enrolled ] [ Designated as safety issue: No ]
Proportion of patients with a confirmed complete or partial response
Same as current
Complete list of historical versions of study NCT01221870 on ClinicalTrials.gov Archive Site
  • Disease control rate [ Time Frame: 12 months from date of first dose of study medication for last patient enrolled ] [ Designated as safety issue: No ]
    Proportion of patients with a confirmed complete or partial response of any duration or stable disease ≥ 3 months in duration
  • Progression-free rate [ Time Frame: 6 months from date of first dose of study medication for last patient enrolled ] [ Designated as safety issue: No ]
    Proportion of patients without disease progression 6 months following the first dose of study medication
  • Durable response rate [ Time Frame: 12 months from date of first dose of study medication for last patient enrolled ] [ Designated as safety issue: No ]
    Proportion of patients with a confirmed complete or partial response ≥ 6 months in duration
  • Duration of response [ Time Frame: 12 months from date of first dose of study medication for last patient enrolled ] [ Designated as safety issue: No ]
    Date when response criteria are first met to the date when progression is first documented
  • Time to progression [ Time Frame: 12 months from date of first dose of study medication for last patient enrolled ] [ Designated as safety issue: No ]
    Date of first dose of study medication to the date when progression is first documented
  • Adverse events [ Time Frame: Up to 30 days after the last dose of study medication for a specific patient ] [ Designated as safety issue: Yes ]
    Incidence of adverse events
Same as current
Not Provided
Not Provided
 
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer

The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer.

Tesetaxel is an orally administered taxane that is in development as first- and second-line treatment for patients with advanced cancers. This study is being undertaken to determine the efficacy and safety of tesetaxel administered as first-line therapy to patients with metastatic breast cancer.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Neoplasm
  • Drug: Tesetaxel once every 3 weeks
    Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
    Other Name: DJ-927
  • Drug: Tesetaxel once weekly
    Tesetaxel capsules orally once every 7 days for 3 consecutive weeks in a 28-day cycle; duration of therapy not to exceed 12 months
    Other Name: DJ-927
  • Experimental: Tesetaxel once every 3 weeks
    Tesetaxel 27 mg/m2 orally once every 21 days for up to 12 months
    Intervention: Drug: Tesetaxel once every 3 weeks
  • Experimental: Tesetaxel once weekly
    Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks in a 28-day cycle for up to 12 months
    Intervention: Drug: Tesetaxel once weekly
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
81
January 2013
October 2012   (final data collection date for primary outcome measure)

Primary Inclusion Criteria:

  • Female
  • At least 18 years of age
  • Histologically or cytologically confirmed adenocarcinoma of the breast
  • Stage IV disease
  • HER2 status negative
  • Measurable disease (revised RECIST; Version 1.1)
  • Eastern Cooperative Oncology Group performance status 0 or 1
  • Life expectancy of at least 3 months
  • Chemotherapy naïve or 1 prior chemotherapy regimen in the adjuvant setting (Prior taxane-based adjuvant therapy allowed provided patient had a disease-free interval of at least 12 months after completing this adjuvant therapy)
  • Prior hormonal therapy, aromatase inhibitor therapy, and immunotherapy allowed
  • Prior radiotherapy in the adjuvant setting allowed provided that less than 25% of the bone marrow had been irradiated
  • Adequate bone marrow, hepatic, and renal function, as specified in the protocol
  • At least 4 weeks and recovery from effects of prior surgery, hormonal therapy, aromatase inhibitor therapy, immunotherapy, radiotherapy, or other therapy with an approved or investigational agent
  • Ability to swallow an oral solid-dosage form of medication

Primary Exclusion Criteria:

  • Known metastasis to the central nervous system
  • History of other malignancy within the last 5 years other than curatively treated basal and squamous cell carcinoma of the skin or carcinoma of the cervix in situ
  • Significant medical disease other than Stage IV breast cancer
  • Presence of neuropathy > Grade 1 (NCI CTC, Version 4.0)
  • History of hypersensitivity to a taxane
  • Need to continue any regularly-taken medication that is a potent inhibitor or inducer of the CYP3A pathway or P-glycoprotein activity
Female
18 Years and older
No
Not Provided
United States
 
NCT01221870
TOB203
No
Genta Incorporated
Genta Incorporated
Not Provided
Principal Investigator: Andrew D Seidman, MD Memorial Sloan-Kettering Cancer Center
Genta Incorporated
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP